Crystal structures of murine angiogenin-2 and -3 – probing ‘structure – function’ relationships amongst angiogenin homologues

Shalini Iyer, Daniel E. Holloway and K. Ravi Acharya

Department of Biology and Biochemistry, University of Bath, UK

Keywords
angiogenin; crystal structure; enzyme mechanism; metal-ion binding ribonuclease A

Correspondence
K. Ravi Acharya, Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath BA2 7AY, UK
Fax: +44 (0) 1225 386 779
Tel: +44 (0) 1225 386 238
E-mail: bsskra@bath.ac.uk

(Received 3 September 2012, revised 14 November 2012, accepted 15 November 2012)

doi:10.1111/febs.12071

Angiogenin (Ang) is a potent inducer of neovascularization. Point mutations in human Ang have been linked to cancer progression and two neurodegenerative diseases: amyotrophic lateral sclerosis and Parkinson’s disease. Intensive structural and functional analyses of Ang have been paramount in assigning functions to this novel homologue of bovine pancreatic RNase A. However, inhibitor-binding studies with crystalline Ang (for designing potential anti-cancer drugs) have been hampered as a result of the inaccessibility of the active site. Experiments with the murine homologues of Ang have not only overcome the obvious practical limitations encountered when studying the role of a human protein in healthy individuals, but also the crystal structures of murine angiogenins (mAng and mAng-4) have revealed themselves to have greater potential for the visualization of small-molecule inhibitor binding at the active site. In the present study, we report the crystal structures of two more murine Ang paralogues, mAng-2 and mAng-3, at 1.6 and 1.8 Å resolution, respectively. These constitute the first crystal structures of an Ang with a zinc ion bound at the active site and provide some insight into the possible mode of inhibition of the ribonucleolytic activity of the enzyme by these divalent cations. Both structures show that the residues forming the putative P1, B1 and B2 subsites occupy positions similar to their counterparts in human Ang and are likely to have conserved roles. However, a less obtrusive conformation of the C-terminal segment in mAng-3 and the presence of a sulfate ion in the B1 subsite of mAng-2 suggest that these proteins have the potential to be used for inhibitor-binding studies. We also discuss the biological relevance of the structural similarities and differences between the different Ang homologues.

Database
The atomic coordinates and structure factors for mAng-2 (3ZBV) and mAng-3 (3ZBW) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ, USA (http://www.rcsb.org/).

Structured digital abstract
• mAng2 and mAng3 bind by x-ray crystallography (View interaction)

Abbreviations
ALS, amyotrophic lateral sclerosis; Ang, angiogenin; CSS, complexation significance score; hAng, human angiogenin; hRI, human ribonuclease inhibitor; mAng, murine angiogenin-1; mAng-2, -3, -4, murine angiogenin orthologues; NLS, nuclear localization sequence; PDB, Protein Data Bank.
Introduction

The bovine pancreatic RNase A superfamily comprises a group of homologous proteins that has been intensely targeted in biochemical, structural, enzymatic and evolutionary studies. Angiogenin (Ang, a 14-kDa protein), an unusual member of the superfamily, is a potent inducer of blood vessel formation that was first isolated from the conditioned medium of cultured HT-29 human colon adenocarcinoma cells based solely on its angiogenic activity [1]. The overall structure of human Ang (hAng), as determined by Acharya et al. [2], not only showed it to have a structural fold similar to that of RNase A [3], but also revealed it to be markedly different in several distinct areas. It can stimulate angiogenesis and, although the ribonucleolytic activity of the protein is rather weak, it is critical for its angiogenic properties [4,5]. Studies with Ang antagonists in athymic mice pointed to a critical role played by this protein in the formation of some human tumours [6–9] and its increased expression has been correlated with diverse cancers in several clinical studies. The ang gene was the first loss-of-function gene identified in amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease characterized by the selective destruction of motor neurons [10–12]. More recently, ang has also been shown to be implicated in Parkinson’s disease [13]. The different mutations identified and characterized so far have all proven to be loss-of-function mutations [14–16].

A detailed structure–function study by Thiyagarajan et al. [17] on several of these Ang-ALS variants provided the first insights into the cellular and molecular mechanisms underlying their role in ALS. Ang, however, has a nonpathological function to play as well, being a constituent of normal plasma [18] and a secreted product of a wide variety of normal cells [19,20]. Indeed, endogenous Ang is a general requirement for cell proliferation and angiogenesis [21].

It has been observed that four different aspects of Ang are required for its angiogenicity: (a) ribonucleolytic activity; (b) stimulation of basement membrane degradation; (c) stimulation of signal transduction; and (d) nuclear translocation. Both the enzymatic and angiogenic activities of hAng are inhibited by its interaction with a 50-kDa leucine-rich repeat protein, human placental RNase inhibitor (hRI) (K_i < 1 fm) [22]. The crystal structure of hRI–hAng [23], in conjunction with mutagenesis studies [24–26], provided insight into the residues involved from both hAng and hRI with respect to forming this extremely tight association. Despite a wealth of information already gathered for the role of human Ang, there are practical limitations in studying the role of the human protein. The murine Ang system, on the other hand, offers an alternative route for studying the physiological and developmental roles of Ang in greater depth.

The murine Ang family, over the course of evolution, has expanded to accommodate six members: mAng (the murine orthologue of hAng), mAng-2 (also known as mAngRP or mAng-related protein), mAng-3, mAng-4, mAng-5 and mAng-6 [27–31] (Fig. 1). Evolutionary studies by Codone et al. [32] suggest that there is functional divergence amongst the mAng paralogues even though the 3D models for the proteins are extremely similar. Experiments have shown that mAng, mAng-3 and mAng-4 have angiogenic activities comparable to that of hAng, whereas mAng-2 is not angiogenic [33–35]. It has also been shown mAng-4 functions as a Paneth cell-derived antimicrobial peptide important in epithelial host defence in the small intestine [36]. mAng-4 is also expressed by the goblet cells of the large intestine after bacterial infection and this expression is controlled by interleukin-3 [37]. At present, only the crystal structures of mAng and mAng-4 [35,38] are known, and the topologies of the two murine enzymes are highly similar to those of hAng and RNase A [2,3]. Previously, we presented in-depth analysis of the structure–function relationships of mAng and mAng-4 by means of site-directed mutagenesis [35,38]. In the present study, we present the X-ray crystal structures of mAng-2 and mAng-3.

We have examined the similarities and differences that these two structures have with the structures of the other two murine paralogues, as well as that of human Ang. Insights gained through comparative analyses of the available structural and functional data provide a means for probing the structure–function relationships amongst the different Ang homologues.

Results

Ribonucleolytic activity

Untagged recombinant proteins were employed throughout the present study. mAng-2 differed from mAng and mAng-3 in that the Pca1 (N-terminal pyroglutamate residue) was replaced by Met(-1)-Gln1. It has been shown previously that such a replacement does not affect the ribonucleolytic activity of hAng owing to the presence of a long N-terminal segment that positions Pca1 far from the active site [33]. Similarly, it is expected that the replacement will not affect the ribonucleolytic activity of the murine Angs assayed in the
present study. Mouse Ang-3 is similar to mAng, with an activity several fold lower than that of hAng, whereas mAng-2 is almost 80% active compared to the human form of the protein (Fig. 2).

**Structural overview**

The crystal structures of mAng-2 and mAng-3 were determined at 1.64 and 1.80 Å resolution, respectively. Crystals for mAng-2 and mAng-3 contained one and two molecules (A and B) in the asymmetric unit, respectively. The final structures comprise residues 4–119 for both chains of mAng-2, whereas mAng-3 chains A and B comprise residues 2–121 and 1–121, respectively. Main-chain electron density for the residues listed above is well ordered. Ramachandran plots indicate that the proportions of non-proline/glycine residues in the most favoured regions are 85.3% and 88% for mAng-2 and mAng-3, respectively, with the remainder of the residues falling in the additional allowed regions of the plot for both the structures. The crystallographic statistics for both structures are provided in Table 1. The main-chain of both mAng-2 and mAng-3 adopts the familiar α/β fold that is characteristic of other Angs and members of the RNase A family (Figs 3 and 4). Both mAng-2 and mAng-3 have two deleted residues, similar to mAng, compared to the sequence of the human enzyme (Fig. 1). There is, however, a close correspondence of the core secondary structure elements when other Angs and RNase A are structurally aligned with mAng-2 and mAng-3 (Fig. 4).

**Dimer interface**

The crystal structure of mAng-3 contains a dimer in the asymmetric unit (Fig. 3). The two protomers of mAng-3 superpose with an rmsd of 0.3 Å. The interface of mAng-3 buries ~450 Å² of solvent-accessible surface as calculated using the PISA interface server (http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html).
The mAng-3 dimer interface has 16 residues per subunit at the interface and, although the residues located at the contact surface include a number of polar and charged side-chains, no ionic interactions and only two hydrogen-bonding contacts are observed.

The PISA server suggests that the dimerization of mAng-3 is not constitutive. The protein–protein interactions are nonspecific and of the same type as those that stabilize specific complexes such as those between a ligand and its receptor or between an antigen and its antibody. They are distributed among several small patches and exhibit poor shape complementarity. Based on the molecular contacts at the interface, PISA calculates a complexation significance score (CSS) that, on a scale from 0 to 1, indicates the probability that a packing interface generated through crystallization might represent a significant feature in solution. The CSS for the dimer interface of mAng-3 is 0, suggesting that dimerization is merely a result of crystal packing.

Interestingly, analysis of the symmetry-related molecules in the mAng-2 crystal structure revealed a two-fold crystallographic dimer that is particularly intimate. The buried surface area at the interface between the two molecules is ~1100 Å², consisting of 33 amino acid residues from each molecule with a total of ten ionic interactions across the interface. Even though PISA calculated a CSS of 0.06 for the mAng-2 crystallographic dimer, the buried interface at the mAng-2 dimer is of considerable size and contains approximately one polar interaction per 150 Å², a high figure [40].

**Interactions mediated by Zn²⁺ and SO₄²⁻ ions**

The crystal structures of both mAng-2 and mAng-3 contain Zn²⁺ and SO₄²⁻ ions. The mAng-2 structure has a total of one Zn²⁺ ion and two SO₄²⁻ ions incorporated into the asymmetric unit by virtue of the crystallization solution, whereas the mAng-3 structure has two Zn²⁺ ions and two SO₄²⁻ ions. Interestingly, in the mAng-2 structure, His82, Asp41 and two water molecules from the protomer in the asymmetric unit, along with His113 (an active site residue) from a symmetry-related mate coordinate the Zn²⁺ ion to complete a penta-coordination (Fig. 5A). A reciprocal set of interactions makes up the symmetry-related Zn²⁺ binding site (Table 2), resulting in a head-to-tail packing. The two Zn²⁺ binding sites in the mAng-3 structure are completely different from each other (Table 2). One of the zinc ions has only two interactions: one with the hydroxyl group of Tyr14 and the other with a water molecule. The second zinc site has five interactions: one with each of His82 and Glu41, two with water molecules and one with an acetate ion. Although it contains no true coordination bonds (all the bond lengths are > 2.3 Å), the second zinc-binding site in mAng-3 is similar to the two zinc-binding sites in the mAng-2 dimer.

The zinc-binding site in mAng-2 resembles one of the copper-binding sites in the RNase A–Cu²⁺ complex (Fig. 5B) [Protein Data Bank (PDB) code: 1AQP] [41] in some aspects. The metal-binding sites share a common catalytic His residue (His113 in mAng-2 and His119 in RNase A). Another similarity between the metal-binding sites in mAng-2 and RNase A is that the ions bind a side-chain carboxyl group (donated by Asp41 and Glu111), respectively. In the RNase A–Cu²⁺ complex structure, three water molecules make up the rest of the coordination bonds at the...
metal-binding site, whereas two water molecules and the ND1 atom of His82 provide the remaining coordination groups for the zinc ion in mAng-2.

The sulfate-binding sites (Table 3) in mAng-2 and mAng-3 are quite different from one another. In the mAng-3 structure, the binding site architecture is very similar to that observed for phosphate and sulfate ions in other Ang structures and both anions ligate the same five P1 subsite residues: Gln12, His13, Lys40, His113 and Phe114 (Fig. 5C). However, in the mAng-2 structure, the central sulfate ion interacts with none of the above P1 subsite residues except for the catalytic lysine (Lys40) (Fig. 5D). The presence of a Zn$^{2+}$ ion at the active site forces the side-chain of Lys40 to orient itself away from the catalytic site. As a result, this ion interacts with the main-chain nitrogen and oxygen atoms of Asp41 and Val42 from opposing symmetry-mates. The binding site of the other sulfate ion in the mAng-2 structure bears no resemblance to any interactions observed within previously elucidated structures of angiogenins. The anion is well coordinated, making hydrogen bonds to Asn67, Arg85, Ser86 and Arg92 (Fig. 5E). The crystallographic mAng-2 dimer presents a symmetry-related sulfate ion that is located directly opposite to the above-mentioned sulfate ion at the other end of the dimer and is equally populated.

Substrate-binding subsites

P1-subsite and the catalytic centre

The catalytic triad at the P1-subsite is robustly conserved in mAng-2 and mAng-3, in the form of His13, Lys40 and His113. When compared with the previously-determined structures of RNase A superfamily members, the positioning and conformation of these three residues indicates that they are involved in the catalysis of the scissile phosphodiester linkage of RNA substrates, whereas the side-chain of Gln12 and the main-chain of Phe114 are most likely engaged in other phosphate-binding interactions [42].

In RNase A homologues, the C-terminal catalytic histidine (His113) may adopt two conformations: conformation A (productive) and conformation B (nonproductive) [43]. In mAng-2, the productive conformation is observed for this residue. There are no intramolecular interactions in mAng-2 that might stabilize His113 in conformation A (as is the case in the hAng structure), although this residue does interact with a zinc ion. In mAng-3, His113 from chain A is observed in conformation B, whereas the same residue takes on both productive and nonproductive conformations in the other chain. The nonproductive conformation of His113 in chain A of mAng-3 forms

![Fig. 4. Topological comparison of Ang homologues. Ribbon diagrams of (A) mAng-2, (B) mAng-3, (C) mAng, (D) mAng-4, (E) hAng (PDB code: 1B1I) [49] and (F) RNase A (PDB code: 1RUV) [76]. Elements of secondary structure are labelled, as are the N- and C-terminal extremities of each structure. Disulfide bonds are shown in black in ball-and-stick form. Also modelled in stick form and coloured green in panel (F) is the uridine vanadate (UVC) molecule. (G) Stereo superposition of the Cα traces of all the six proteins. Colours correspond to those used in (A)–(F).](image-url)
a hydrogen bond with an oxygen atom of the nearby sulfate ion via its ND1 atom. Its NE2 atom interacts with a symmetry-related Glu107 (the counterpart of Glu111 in RNase A) instead of a water molecule as has been observed for conformation B in some structures of RNase S [44,45]. The conformation of His13 and Phe114 is the same in mAng-2 and mAng-3 as that seen in the hAng structure. The orientation of Lys40, however, differs between the two murine angiogenins. In mAng-3, the side-chain of Lys40 points towards the active site of its own protomer. In mAng-2, Lys40 is expelled and ligates a sulfate ion occupying the active site of a symmetry-related molecule.

**B1-subsite and the C-terminal segment**

The B1-subsite, which is well characterized in RNase A [46,47] binds the nucleotide base upstream of the

---

**Table 1. Crystallographic statistics.**

|                      | mAng-2 | mAng-3 |
|----------------------|--------|--------|
| Data collection      |        |        |
| X-ray wavelength (Å) | 0.87   | 0.97   |
| Space group          | I4122  | P21    |
| Cell dimensions (Å)  | a = b = 89.72; a = 28.2; c = 64.55       |
|                      | b = 95.67; c = 41.66                      |
| Resolution (Å)       | 40–1.64 | 40–1.8 |
| Number of reflections measured | 66 711 | 55 483 |
| Number of unique reflections | 14 855 | 15 155 |
| Rsym (outermost shell) (%) | 6.7 (24.5) | 6.2 (39.5) |
| I/σ(I) (outermost shell) | 16.9 (5.2) | 15.9 (2.0) |
| Completeness (outermost shell) (%) | 97.0 (99.0) | 75.4 (23.2) |

| Refinement            |        |        |
| Rcryst (%)            | 19.8   | 16.5   |
| Rfree (%)             | 20.3   | 22.6   |
| Number of atoms (total) | 1118  | 2207  |
| Protein atoms         | 962    | 1969   |
| Water                 | 139    | 222    |
| Ions                  |        |        |
| Zn2+                  | 1      | 2      |
| SO4^2-                | 10     | 10     |
| Ligand                | 6 (glycerol) | 4 (acetate) |
| rmsd from ideality    |        |        |
| Bond length (Å)       | 0.008  | 0.008  |
| Bond angles (°)       | 1.257  | 1.119  |
| Mean B-factor (Å²)    | 19.4   | 18.7   |

*a* Outermost shell (Å): mAng-2, 1.70–1.64 Å; mAng-3, 1.9–1.8 Å.  
*b* \( R_{sym} = \sum |I_j - \langle I\rangle|/\sum \langle I\rangle \) where \( I_j \) is the observed intensity of reflection \( j \), and \( \langle I\rangle \) is the mean intensity of multiple observations.  
*c* \( R_{cryst} = \sum |F_o - |F_c|/\sum |F_o| \), where \( F_o \) and \( F_c \) are the observed and calculated structure factor amplitudes, respectively.  
*d* \( R_{free} \) is equal to \( R_{cryst} \) for a randomly selected 5% reflections not used in the refinement.
Table 2. Zinc ion binding in the active site of mAng-2 and mAng-3. SYM, symmetry related molecule.

| Source | Target | Distance (Å) |
|--------|--------|--------------|
| Zn     | His 113B NE2 (SYM) | 2.0 |
|        | Water (SYM) | 2.2 |
|        | His 82A ND1 | 2.1 |
|        | Water (SYM) | 2.2 |
|        | Asp 41A OD1 | 2.0 |
| Zn (SYM) | His 113A NE2 | 2.0 |
|        | Water | 2.2 |
|        | His 82B ND1 (SYM) | 2.1 |
|        | Water | 2.2 |
|        | Asp 41B OD1 (SYM) | 2.0 |
|        | Zn 1 | Tyr 14A OH | 2.8 |
|        | Water | 2.7 |
|        | His 82A ND1 | – |
|        | Water | – |
|        | Asp 41A OD1 | – |

The B₂-subsite and the H₃-B₂ loop

The B₂-subsite binds the nucleotide base downstream of the scissile phosphodiester linkage. In RNase A, the residues that make up this subsite are contributed by a loop (amino acids 65–72) that is stabilized by a disulfide bridge [51]. In angiogenins, however, this disulfide bond is not conserved, and the B₂-subsite is relatively rudimentary [38,49]. In mAng-2 and mAng-3, the three residues predicted to make up this subsite are Leu68 (mAng-2)/Phe68 (mAng-3), Gly105 (mAng-2)/Ala105 (mAng-3) and His113. These residues occupy positions similar to their hAng, mAng and mAng-4 counterparts and hence support the notion that any interactions they make with the substrate will be conserved.

Cell-binding site and the nuclear localization sequence (NLS)

Three consecutive positive charges (Arg31-Arg32-Arg33) comprise the NLS of hAng, of which Arg33 is the most crucial for nuclear targeting [52,53]. Although the essential arginine is conserved (as Arg33 in mAng-2 and mAng-3), substitution of Arg31 for Val31 in mAng-2 alters the NLS chemical character. Arg31 → Lys31 substitution in mAng-3 is subtle and preserves a surface charge distribution similar to that of hAng. Looking at the surface of mAng-2 and mAng-3, a series of positively-charged residues can be seen dotted around the NLS region (Fig. 7). The amino acid substitutions conjectured to provide a noncontiguous basic patch in mAng-4 [35] could be hypothesized to do the same in mAng-2 and mAng-3.

The cell-binding site in hAng comprises residues 60–68 and Asn109 [54,55]. The sequence of the 60–68 segment is fairly well conserved in mAng but varies more in the other murine angiogenins (Fig. 1). In this region, the Cα traces of mAng-2 and mAng-3 (Fig. 8) deviate from the conformation observed for hAng [2], mAng [38] and mAng-4 [35]. Similar to
Table 3. Potential hydrogen bonds (identified using HBPLUS [77]) between protein and anionic ligands (PO₄ and/or SO₄) in the mAng-2, mAng-3, mAng-1 and hAng complexes. The upper limit for the donor–acceptor distance was 3.3 Å; the lower limit for the donor–hydrogen–acceptor angle is 105°. Bond angles are not given where the hydrogen position is ambiguous.

| Ligand acceptor atom | mAng-2–SO₄ | mAng-3–SO₄ | mAng–PO₄ (PDB code: 2BWL) | mAng–SO₄ (PDB code: 2BWK) | hAng–PO₄ (PDB code: 1HBY) |
|----------------------|-------------|-------------|-----------------------------|-----------------------------|-----------------------------|
| O1                   | B Lys40 NZ (2.8; 144.5) | B Phe114 O (2.8)a | His13 NE2 (2.8; 139) | Phe114 N (2.8; 166) | His113 NE2 (3.2; 136) |
|                      | B Val42 N (3.0; 150.5) | Water (2.6) | His114 N (3.0; 166) |                | Leu115 N (3.0; 169) |
|                      | B Asp41 N (3.1)a | |                |                | |
| O2                   | A Lys40 NZ (2.9; 163.2) | B Gin12 OE1 (3.1)a | Gin12 NE2A (2.9; 117) | Gin12 NE2B (2.8; 112) | Gln12 NE2 (2.6; 119) |
|                      | A Val42 N (2.9; 147.5) | B His13 NE2 (2.7)a | Lys40 NZ (2.9; 136) | His13 NE2 (3.0; 160) | His13 NE2 (3.2; 158) |
|                      | A Asp41 N (3.1)a | B Lys40 NZ (2.9; 133) | | Lys40 NZ (3.1; 130) | Lys40 NZ (3.2; 105) |
|                      | | Water (2.8) | | | |
| O3                   | A Lys40 NZ (3.3)a | B His13 NE2 (2.9)a | His113 ND1A (2.9; 153)b | His113 ND1B (2.9; 158) | His114 ND1 (3.4; 146) |
|                      | B Asp41 N (2.8)a | B His113 ND1A (3.2)a | His113 ND1B (3.2; 148)b | | |
|                      | | B Phe114 N (2.8; 165) | His113 ND1A (3.1; 153)c | | |
|                      | | Water (3.0) | | | |
| O4                   | A Asp41 N (3.0; 173.1)a | B His113 ND1A (2.9; 132) | – | – | – |
|                      | B Lys40 NZ (3.3)a | B His113 ND1B (3.4)a | – | – | – |
|                      | | Water (2.4) | | | |
| O1                   | | | | | |
| O2                   | A His13 NE2 (2.1)a | A Phe114 N (2.8; 158) | Water (2.8) | | |
|                      | | A His13 NE2 (2.1)a | | | |
| O3                   | A Gin12 NE2 (3.3)a | Water (2.9)a | | | |
| O4                   | A Gin12 NE2 (3.2)a | A His13 NE2 (2.9; 160) | A Lys40 NZ (3.0; 137) | A Lys40 NZ (3.0; 137) | |
|                      | | Water (3.0); Water (3.4)a | | | |

a Alternative interactions identified by CONTACT [78]. b,c Interactions with orientation A and B of phosphate ion in mAng–PO₄ (PDB code: 2BWU) [38].
that observed in mAng and mAng-4, this deviation is brought about by the replacement of the Glu-Asn sequence in hAng with a single Gly residue, upstream of the 60–68 loop region (a substitution found in all the murine angiogenins). Mutagenesis studies have highlighted Asn61 and Arg66 of hAng as amino acid residues crucial for angiogenic activity [54,55]. The mAng-2 sequence has a Asn→Lys substitution similar to that in mAng-4 at position 60 (the counterpart of Asn61 in hAng and Lys59 in mAng-4). The critical Arg66 of hAng is replaced by a Gly residue (position 65) in both mAng-2 and mAng-3. Reduced steric constraints at this position on account of this glycine give the adjacent residues some freedom to deviate from the positions of their hAng counterparts, which is reflected in the rmsd of these residues. mAng-2 deviates the most from hAng with a Cα rms deviation of 2.35 Å (1.08 Å and 2.09 Å for mAng-3 and mAng-4, respectively). The position and conformation of residue Arg65 in mAng (equivalent to Arg66 of hAng) is similar to that of hAng (Cα displacement of 0.82 Å).

Discussion
We have reported the crystal structures of two murine Ang paralogues. Even though these structures are broadly similar to the previously elucidated 3D structures of hAng, mAng and mAng-4, there are important albeit subtle differences amongst these proteins that have been highlighted in the course of the present study. These Ang structures have enabled us to carry out a more rigorous and authentic structure-based analysis than that presented by Codoñer et al. [32], which was based on 3D structural models for the different murine angiogenins. The most important difference between our analysis, based on our experimentally observed data, and theirs is the configuration of the catalytic centre in mAng-2. Codoñer et al. [32] suggest that a possible reason for the angiogenic incompetence of mAng-2 (unlike mAng) is a more effective blockage of its active site. In our structures, however, we observe that mAng-2 has a more open active site than hAng or mAng. This observation is consistent with the fact that mAng-2 has a three-fold more active than hAng (Fig. 2). Codoñer et al. [32] make a similar prediction for mAng-5 with regard to its lack of angiogenic activity, which can only be validated when the 3D structure is elucidated.

Metal-ion binding
Divalent metal ions, such as Cu²⁺ and Zn²⁺, have been shown to inhibit the ribonucleolytic activity of hAng [56]. Also, Cu²⁺ appears to prevent the forma-
tion of the Ang–RI complex and is considered to play an important role in regulating its activity [57]. Soncin et al. [58] showed that hAng directly interacts with copper and zinc ions. This interaction was found to result in the formation of Ang dimers and increased binding of the protein to lower affinity extracellular matrix binding sites. The dimers observed in the crystal lattice for mAng-2 and mAng-3 provide the first visual confirmation of the binding of an Ang to a divalent cation. It has been reported that RNase A binds copper at several sites (also involving a dimer of proteins) and its enzymatic activity is inhibited by copper and zinc, similar to angiogenin [56]. The crystal structures of zinc-bound mAng-2 and mAng-3 provide some insight into the possible mode of inhibition of ribonucleolytic activity of the enzyme by these divalent cations. The present structures suggest that the tethering of the catalytically essential His113 (His114 in hAng) to a zinc ion at the active site could potentially prevent the participation of the active site His residue in general base catalysis. The mAng-2 structure also reveals Lys40 to be reoriented out of the active site pocket, making it ineffective as a catalytic residue. It is possible that copper binds hAng in a similar fashion. Perhaps other residues (e.g. Tyr14 as observed in the mAng-3 structure) are also recruited. It has been reported that iodination of hAng modifies the elution profile of the protein during copper-affinity chromatography [58]. Because tyrosine residues are susceptible to iodination, Tyr14, which is in close proximity to His8 and His13, is a likely candidate. Interaction of mAng-2 His82 with zinc suggests that the corresponding loop region of hAng, which is known to interface with RI might also be affected by the binding of zinc ions. In hAng, this loop contains residues G85 and G86, which have been shown to interact with human RI (PDB code: 1A4Y) [23]. Mutation studies have further shown that changes to these residues increase the
angiogenic activity of the human protein and this increase can be attributed to a decrease in its affinity for RI [26]. This provides a possible explanation regarding how copper might prevent the formation of the hAng–RI complex. Although the precise identity of the amino acid residues involved in binding copper are yet to be determined and it is not clear as to which mode of dimerization is adopted by hAng, the ions bound in the two structures reported in the present study give an insight into how divalent cations such as copper and zinc might interact with Ang and potentially modulate its function.

**Ribonuclease A activity and cell binding**

Despite structural similarity amongst the angiogenins, the enzymatic properties of these proteins exhibit some differences, as might be predicted from the sequence variations at amino acid positions that are involved in contributing to the catalytic properties of these proteins. All mAngs have a lower level of catalytic efficiency compared to hAng. The specific activity of mAng-3 is similar to that of mAng and mAng-4 [35]. mAng-2, on the other hand, appears to be able to cleave tRNA more efficiently (Fig. 2). Within the Ang family, it is considered that enhanced hydrophobic interactions between the C-terminus and the main body of the protein presents the enzyme with a higher energy barrier for substrate turnover and hence leads to suppression of catalytic activity. Studies whereby these hydrophobic interactions were weakened through mutagenesis or by the addition of methanol have shown that the catalytic prowess of hAng increases by three- to four-fold even though the substrate specificity remains unaffected [50,59]. The C-terminal segment of the angiogenins, in general, is more nonpolar in nature than that of RNase A (Fig. 9). Hydrophobic interactions in the C-terminal region are potentiated in the murine angiogenins by the presence of Phe residues at positions 114 and 118 (113 and 117 for mAng-4), which may explain the lower catalytic efficiency of murine angiogenins compared to hAng, which possess Leu and Ile at the corresponding positions. Unfavourable positioning of the glutamate residue in mAngs (counterparts to hAng Gln117) causes obstruction of the pyrimidine-binding site. mAng (possessing Phe118/ Phe119 and hence having a more hydrophobic C-terminus than other mAngs) and mAng-4 (possessing Phe117/Ile118) have a closed conformation similar to that of the human protein in which the side-chain of Phe119 (mAng)/Ile118 (mAng-4) also obstructs the substrate-binding site (Fig. 8). However, the side-chains of the equivalent pair of amino acids (Phe118/Ile119) do not block the active site in mAng-2 and mAng-3 (Fig. 6). This partial opening of the active site may explain why mAng-2 is enzymatically more efficient than is mAng and mAng-4; however, it does not explain why mAng-3 is not. Perhaps this can be rationalized by looking at the sequence of the different angiogenins at the N-terminal end (Fig. 1). Russo et al. [59] provided kinetic evidence for the interaction of hAng Arg5 with a peripheral component of RNA substrates. They reported that hAng has functional phosphate binding sites on both the S' and 3' side of the B2 subsite with greatest affinity for a 2'-phosphate. The Arg residue at this position is conserved across all angiogenins. However, amino acids on either side of this residue vary among the human and murine proteins. Although mAng-2 has the same residues before and after Arg5 (Ser4 and Tyr6), Ser4 is replaced by Tyr4 in mAng-3. It is possible that the larger side-chain of the Tyr residue perturbs the base binding site in mAng-3 causing a reduction in ribonucleolytic activity.

**Angiogenin–heparin interactions**

Past studies have revealed that at least 12 saccharide units are required to inhibit the adhesion of hAng to HT-29 cells [60]. The three contiguous arginines, Arg31/Arg32/Arg33, along with Arg70 were identified as important residues that mediate interactions with heparin to support cell adhesion to hAng. Harper and Vallee [61] also showed that heparin prevents trypsin-mediated cleavage of hAng at Lys60, thereby suggesting that heparin might also bind to this region of hAng. The $\text{SO}_4^{2-}$ ions in the mAng-2 structure occupy sites between two mAng-2 molecules along a plane perpendicular to the dimer axis (Fig. 3), forming a crystallographic dimer. One of the $\text{SO}_4^{2-}$ ions is shared between the two protomers. The shared $\text{SO}_4^{2-}$ ion is located near the active site of the enzyme and ligates with P1 (Lys40) and B1 (Val42) subsite residues of both the mAng-2 protomers. Its interaction with Lys40 renders this residue unavailable to the catalytic core. Interaction with Asn67, Arg85, Ser86, and Arg92, observed at the other sulfate site, is almost exactly mirrored by the symmetry-related sulfate binding site at the opposite end of the dimer (Table 3). The side-chain orientation of Arg92 is maintained by its interaction with the main-chain carbonyl oxygen of Arg66. Although none of the sulfate ions in the mAng-2 structure bind the region equivalent to that comprising the Arg cluster in hAng, two of the sulfate ions do bind Arg66 and Asn67. These residues are located in the loop region equivalent to the segment of hAng (residues 60–68) that has been implicated in cell binding.
Fig. 9. Hydrophobic packing of the C-terminus. (A, B) mAng-2; (C, D) mAng-3; (E, F) mAng; (G, H) mAng-4; (I, J) hAng; (K, L) RNase A. Hybrid representation in which the secondary structures are shown in schematic form and side-chains of the C-terminal hydrophobic residues (yellow), the pocket base (blue) and collar (red) are shown in both ball-and-stick form, as well as opaque space-filling spheres. (B), (D), (F), (H), (J) and (L) were obtained from (A), (C), (E), (G), (I) and (K), respectively, by a 90° rotation about the x-axis.
Although the two sites are 37–38 Å apart, it is possible that loop 60–68 may form a subsite for heparin binding. The sulfate ions in mAng-2 are placed such that the distance between the shared anion and the one binding near the loop regions of 63–71 and 84–92 is ~16 Å. A heparin molecule of five to six saccharides in length would suffice to bridge this distance, with the heparin chain extending from the tri-arginine cluster in the direction of the cell-binding site.

Light scattering measurements have determined a binding density of one hAng molecule for every five or six monosaccharide units [60]. This is in contrast to the requirement of at least 12 saccharide units for inhibition of the capacity of hAng to support cell adhesion [60]. In this regard, the fortuitous positioning of the sulfate ions in mAng-2 may provide some clues to the possible mode of heparin binding. The above findings suggest that hAng might form dimers to interact with the anionic heparin chain. The cell-binding site is critical for nuclear translocation of angiogenin and it may be that internalization of angiogenin is inhibited upon interaction with heparin as a result of the recruitment of residues from the cell-binding region. This can be explored further by elucidation of the structure of an angiogenin–heparin complex.

**Experimental procedures**

**Protein expression and purification**

Expression plasmids for both mAng-2 and mAng-3, each with a single copy of the coding sequence inserted into pET22b(+), (Novagen, Madison, WI, USA), were available from a previous study [63]. The expression plasmids were used to transform BL21-CodonPlus(DE3)-RII cells (Stratagene, La Jolla, CA, USA). Expression and purification of the recombinant proteins followed the method described by Holloway et al. [63]. Briefly, protein expression, induced by the addition of 1 mM isopropyl thio-β-D-galactoside at 37 °C, was directed to the insoluble fraction. These inclusion bodies were solubilized in 7 M guanidine hydrochloride and subjected to arginine-assisted refolding at pH 8.0. The refolded proteins were then purified by SP-Sepharose (cation-exchange) chromatography followed by C4 reversed-phase HPLC. The purified proteins were lyophilized and reconstituted in HPLC-grade water. The purity and the homogeneity of the proteins (> 98%) were monitored by SDS/PAGE. Protein concentration was determined by measuring UV absorbance and using an estimated ε280 [64] of 14 815 m−1 cm−1 for mAng-2 and 17 795 m−1 cm−1 for mAng-3. Both mAng-2 and mAng-3 were authenticated by ESI TOF-MS. The recorded molecular mass of each protein was accurate to within 1 Da of the predicted mass.

**Ribonucleolytic activity assay**

tRNA cleavage assays were carried out as described by Shapiro et al. [65,66]. Assays were conducted using 2 mg·mL−1 yeast tRNA (Sigma, St Louis, MO, USA), 0.1 mg·mL−1 BSA (Worthington Biochemical Corp., Freehold, NJ, USA) and six different concentrations (in triplicates) of each of the test proteins. hAng was used as reference sample. A260 was recorded as a measure of RNase activity. The readings were plotted against the protein concentration for each protein and the magnitude of activity was used in the calculation of relative activities. The activity of hAng was found to be in accordance with previous measurements.

**Crystallization and data collection**

Crystals of mAng-2 and mAng-3 were grown at 16 °C by the hanging-drop vapor-diffusion method. mAng-2 crystallized within 3–4 weeks when crystallization buffer containing 25% poly(ethylene glycol) 550 monomethyl ether, 0.1 M 2-(N-morpholinoethanesulfonic acid, pH 6.5 and 0.01 M ZnSO4 was mixed with an equal volume of protein solution (16 mg·mL−1 in water). Diffraction data were collected from a single crystal, flash-frozen at 100 K on PX 9.6 at the Synchrotron Radiation Source (Daresbury, UK). Data were processed and scaled using HKL2000 [67,68] in the tetragonal space group, I4,22. mAng-3 was crystallized by equilibrating the drops containing protein solution (25 mg·mL−1 in water) and reservoir solution (1:1) against crystallization buffer (25% poly(ethylene glycol) 3350, 20 mM sodium citrate, pH 4.6 and 2% glycerol). Diffraction data were collected from a single crystal, flash-frozen to 100 K on PX 14.2 at the Synchrotron Radiation Source. Data for mAng-3 were processed and scaled using HKL2000 [67,68] in the monoclinic space group, P21. Details of the data collection and processing for both mAng-2 and mAng-3 are given in Table 1.

**Structure determination and refinement**

Initial phases for both the structures were obtained using AMORE [69], employing the coordinates of mAng (PDB code: 2BK] [38] as the search model. The search model was tailored such that residues non-identical between mAng and mAng-2/mAng-3 were mutated to alanine. Data in the range 4–20 Å were used for both rotation and translation function searches. Clear solutions were obtained for both mAng-2 and mAng-3. Inspection of the resultant models with COOT [70] revealed a convincing crystallographic packing environment without any stereochemical clashes.
Crystallographic refinement was carried out using refmac [71]. A random set of reflections comprising 2.6% (mAng-2) and 5.2% (mAng-3) was excluded from the full data set for calculation of the cross-validatory free-R factor (Rfree) to monitor the refinement trend [72]. After the initial round of refinement, the mutated residues in the model were replaced with the authentic mAng-2/mAng-3 residues on the basis of mFo – DFo electron density. Cycles of restrained refinement interspersed with electron density map calculations and manual model building using coot [70] progressively improved the structure. In the final stages of refinement, water molecules with peaks > 3σ in the mFo – DFo electron density map were incorporated into the structures. Zn²⁺ and SO₄²⁻ ions were also incorporated in both structures. Structure validation was carried out using molprobity [73] and the RCSB PDB Validation Suite (http://deposit.rcsb.org/validate/). Refinement statistics for the finalized structures of mAng-2 and mAng-3 are provided in Table 1. Figures were prepared using pymol (http://www.pymol.org).

Acknowledgements

We thank Mr David Carr and Dr Umesh Singh for their contributions during the preliminary stages of the structural work described in this report and Dr Anneke Lubben for the MS analyses. This work was supported by the Wellcome Trust (UK) through a Programme Grant (number 083191) to K.R.A.

References

1 Fett JW, Strydom DJ, Lobb RR, Alderman EM, Bethune JL, Riordan JF & Vallee BL (1985) Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry 24, 5480–5486.

2 Acharya KR, Shapiro R, Allen SC, Riordan JF & Vallee BL (1994) Crystal structure of human angiogenin reveals the structural basis for its functional divergence from ribonuclease. Proc Natl Acad Sci USA 91, 2915–2919.

3 Wlodawer A, Svensson LA, Sjölin L & Gilliland GL (1988) Structure of phosphate-free ribonuclease A refined at 1.26 Å. Biochemistry 27, 2705–2717.

4 Shapiro R, Fox EA & Riordan JF (1989) Role of lysines in human angiogenin: chemical modification and site-directed mutagenesis. Biochemistry 28, 1726–1732.

5 Shapiro R & Vallee BL (1989) Site-directed mutagenesis of histidine-13 and histidine-114 of human angiogenin. Alanine derivatives inhibit angiogenin-induced angiogenesis. Biochemistry 28, 7401–7408.

6 Olson KA, Fett JW, French TC, Key ME & Vallee BL (1995) Angiogenin antagonists prevent tumor growth in vivo. Proc Natl Acad Sci USA 92, 442–446.

7 Olson KA, Byers HR, Key ME & Fett JW (2001) Prevention of human prostate tumor metastasis in athymic mice by antisense targeting of human angiogenin. Clin Cancer Res 7, 3598–3605.

8 Olson KA, Byers HR, Key ME & Fett JW (2002) Inhibition of prostate carcinoma establishment and metastatic growth in mice by an antiangiogenin monoclonal antibody. Int J Cancer 98, 923–929.

9 Kao RY, Jenkins JL, Olson KA, Key ME, Fett JW & Shapiro R (2002) A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity. Proc Natl Acad Sci USA 99, 10066–10071.

10 Greenway MJ, Andersen PM, Russ C, Ennis S, Cashman S, Donaghy C, Patterson V, Swingler R, Kieran D, Prehn J, et al. (2006) ANG mutations segregate with familial and ‘sporadic’ amyotrophic lateral sclerosis. Nat Genet 38, 411–413.

11 Subramanian V & Feng Y (2007) A new role for angiogenin in neurite growth and pathfinding: implications for amyotrophic lateral sclerosis. Hum Mol Genet 16, 1445–1453.

12 van Es MA, Schelhaas HJ, van Vught PW, Ticozzi N, Andersen PM, Groen EJ, Schulte C, Blauw HM, Koppers M, Diekstra FP, et al. (2011) Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann Neurol 70, 964–973.

13 Steindinger TU, Standaert DG & Yacoubian TA (2011) A neuroprotective role for angiogenin in models of Parkinson’s disease. J Neurochem 116, 334–341.

14 Wu D, Yu W, Kishikawa H, Folkther RD, Ifratre AJ, Shen Y, Xin W, Sims K & Hu GF (2007) Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis. Ann Neurol 62, 609–617.

15 Crabtree B, Thiagarajan N, Prior SH, Wilson P, Iyer S, Fers T, Shapiro R, Brew K, Subramanian V & Acharya KR (2007) Characterization of human angiogenin variants implicated in amyotrophic lateral sclerosis. Biochemistry 46, 11810–11818.

16 Subramanian V, Crabtree B & Acharya KR (2008) Human angiogenin is a neuroprotective factor and amyotrophic lateral sclerosis associated angiogenin variants affect neurite extension/pathfinding and survival of motor neurons. Hum Mol Genet 17, 130–149.

17 Thiagarajan N, Ferguson R, Subramanian V & Acharya KR (2012) Structural and molecular insights into the mechanism of action of human angiogenin-ALS variants in neurons. Nat Commun 3, 1121.

18 Shapiro R, Strydom DJ, Olson KA & Vallee BL (1987) Isolation of angiogenin from normal human plasma. Biochemistry 26, 5141–5146.

19 Rybak SM, Fett JW, Yao QZ & Vallee BL (1987) Angiogenin mRNA in human tumor and normal cells. Biochem Biophys Res Commun 146, 1240–1248.
20 Moenner M, Gusse M, Hatzi E & Badet J (1994) The widespread expression of angiogenin in different human cells suggests a biological function not only related to angiogenesis. Eur J Biochem 226, 483–490.

21 Kishimoto K, Liu S, Tsuchi T, Olson KA & Hu GF (2005) Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene 24, 445–456.

22 Lee FS & Vallee BL (1989) Binding of placental ribonuclease inhibitor to the active site of angiogenin. Biochemistry 28, 3556–3561.

23 Papageorgiou AC, Shapiro R & Acharya KR (1997) Molecular recognition of human angiogenin by placental ribonuclease inhibitor – an X-ray crystallographic study at 2.0 Å resolution. EMBO J 16, 5162–5177.

24 Chen CZ & Shapiro R (1999) Superadditive and subadditive effects of “hot spot” mutations within the interfaces of placental ribonuclease inhibitor with angiogenin and ribonuclease A. Biochemistry 38, 9273–9285.

25 Shapiro R, Ruiz-Gutierrez M & Chen CZ (2000) Analysis of the interactions of human ribonuclease inhibitor with angiogenin and ribonuclease A by mutagenesis: importance of inhibitor residues inside versus outside the C-terminal “hot spot”. J Mol Biol 302, 497–519.

26 Dickson KA, Kang DK, Kwon YS, Kim JC, Leland PA, Kim BM, Chang SI & Raines RT (2009) Ribonuclease inhibitor regulates neovascularization by human angiogenin. Biochemistry 48, 3804–3806.

27 Bond MD & Vallee BL (1990) Isolation and sequencing of mouse angiogenin DNA. Biochem Biophys Res Commun 171, 988–995.

28 Brown WE, Nobile V, Subramanian V & Shapiro R (1995) The mouse angiogenin gene family: structures of an angiogenin-related protein gene and two pseudogenes. Genomics 29, 200–206.

29 Fu X & Kamps MP (1997) E2a-Pbx1 induces aberrant expression of tissue-specific and developmentally regulated genes when expressed in NIH 3T3 fibroblasts. Mol Cell Biol 17, 1503–1512.

30 Strydom DJ (1998) The angiogenins. Cell Mol Life Sci 54, 811–824.

31 Cho S, Beintema JJ & Zhang J (2005) The ribonuclease A superfamily of mammals and birds: identifying new members and tracing evolutionary histories. Genomics 85, 208–220.

32 Codoeüner FM, Alfonso-Lœches S & Fares MA (2010) Mutational dynamics of murine angiogenin duplicates. BMC Evol Biol 10, 310–314.

33 Nobile V, Vallee BL & Shapiro R (1996) Characterization of mouse angiogenin-related protein: implications for functional studies on angiogenin. Proc Natl Acad Sci USA 93, 4331–4335.

34 Fu X, Roberts WG, Nobile V, Shapiro R & Kamps MP (1999) mAngiogenin-3, a target gene of oncprotein E2a-Pbx1, encodes a new angiogenic member of the angiogenin family. Growth Factors 17, 125–137.

35 Crabtree B, Holloway DE, Baker MD, Acharya KR & Subramanian V (2007) Biological and structural features of murine angiogenin-4, an angiogenic protein. Biochemistry 46, 2431–2443.

36 Hooper LV, Stappenbeck TS, Hong CV & Gordon JJ (2003) Angiogenins: a new class of microbicidal proteins involved in innate immunity. Nat Immunol 4, 269–273.

37 Forman RA, deSchoolmeester ML, Hurst RJ, Wright SH, Pemberton AD & Else KJ (2012) The goblet cell is the cellular source of the anti-microbial angiogenin 4 in the large intestine post Trichuris muris infection. PLoS ONE 7, e42248–e42254.

38 Holloway DE, Chavali GB, Hares MC, Subramanian V & Acharya KR (2005) Structure of murine angiogenin: features of the substrate- and cell-binding regions and prospects for inhibitor-binding studies. Acta Crystallogr D Biol Crystallogr 61, 1568–1578.

39 Ramachandran GN, Ramakrishnan C & Sasisekharan V (1963) Stereochemistry of polypeptide chain configurations. J Mol Biol 7, 95–99.

40 Lo Conte L, Chothia C & Janin J (1999) The atomic structure of protein–protein recognition sites. J Mol Biol 285, 2177–2198.

41 Balakrishnan R, Ramasubbu N, Varughese KI & Parthasarathy R (1997) Crystal structures of the copper and nickel complexes of RNase A: metal-induced interprotein interactions and identification of a novel copper binding motif. Proc Natl Acad Sci USA 94, 9620–9625.

42 Raines RT (1998) Ribonuclease A. Chem Rev 98, 1045–1066.

43 Lequin O, Thuring H, Robin M & Lallemant JY (1997) Three-dimensional solution structure of human angiogenin determined by 1H,15N-NMR spectroscopy – characterization of histidine protonation states and pKa values. Eur J Biochem 250, 712–726.

44 Martin PD, Doscher MS & Edwards BF (1987) The refined crystal structure of a fully active semisynthetic ribonuclease at 1.8Å resolution. J Biol Chem 262, 15930–15938.

45 Kim EE, Varadarajan R, Wyckoff HW & Richards FM (1992) Refinement of the crystal structure of ribonuclease S. Comparison with and between the various ribonuclease A structures. Biochemistry 31, 12304–12314.

46 Richards FM, Wyckoff HW & Allewell N (1970) The origin of specificity in binding: a detailed example in a protein-nucleic acid interaction. In The Neurosciences:
Second Study Program (Schmitt FO, ed), pp. 901–912. Rockefeller University Press, New York.

47 Wlodawer A & Šjolin L (1983) Structure of ribonuclease A: results of joint neutron and X-ray refinement at 2.0-Å resolution. Biochemistry 22, 2720–2728.

48 delCardayre SB & Raines RT (1995) A residue to residue hydrogen bond mediates the nucleotide specificity of ribonuclease A. J Mol Biol 252, 328–336.

49 Leonidas DD, Shapiro R, Allen SC, Subbarao GV, Veluraja K & Acharya KR (1999) Crystal structures of native human angiogenin and two active site variants: implications for the unique functional properties of an enzyme involved in neovascularisation during tumour growth. J Mol Biol 285, 1209–1233.

50 Leonidas DD, Shapiro R, Subbarao GV, Russo A & Acharya KR (2002) Crystallographic studies on the role of the C-terminal segment of human angiogenin in defining enzymatic potency. Biochemistry 41, 2552–2562.

51 Zegers I, Maes D, Dao-Thi MH, Poortmans F, Palmer R & Wyns L (1994) The structures of RNase A complexed with 3′-CMP and d(CpA): active site conformation and conserved water molecules. Protein Sci 3, 2322–2339.

52 Moroianu J & Riordan JF (1994) Identification of the nucleolar targeting signal of human angiogenin. Biochem Biophys Res Commun 203, 1765–1772.

53 Jans DA, Xiao CY & Lam MH (2000) Nuclear targeting signal recognition: a key control point in nuclear transport? BioEssays 22, 532–544.

54 Hallahan TW, Shapiro R & Vallee BL (1991) Dual site model for the organogenic activity of angiogenin. Proc Natl Acad Sci USA 88, 2222–2226.

55 Hallahan TW, Shapiro R, Strydom DJ & Vallee BL (1992) Importance of asparagine-61 and asparagine-109 to the angiogenic activity of human angiogenin. Biochemistry 31, 8022–8029.

56 Lee FS & Vallee BL (1989) Characterization of ribonucleolytic activity of angiogenin towards tRNA. Biochem Biophys Res Commun 161, 121–126.

57 Badet J, Soncin F, Guitton JD, Lamare O, Cartwright T & Barritault D (1989) Specific binding of angiogenin to calf pulmonary artery endothelial cells. Proc Natl Acad Sci USA 86, 8427–8431.

58 Soncin F, Guitton JD, Cartwright T & Badet J (1997) Interaction of human angiogenin with copper modulates angiogenin binding to endothelial cells. Biochem Biophys Res Commun 236, 604–610.

59 Russo N, Acharya KR, Vallee BL & Shapiro R (1996) A combined kinetic and modeling study of the catalytic center subsites of human angiogenin. Proc Natl Acad Sci USA 93, 804–808.

60 Soncin F, Strydom DJ & Shapiro R (1997) Interaction of heparin with human angiogenin. J Biol Chem 272, 9818–9824.

61 Harper JW & Vallee BL (1988) Conformational characterization of human angiogenin by limited proteolysis. J Protein Chem 7, 355–363.

62 Shapiro R & Vallee BL (1992) Identification of functional arginines in human angiogenin by site-directed mutagenesis. Biochemistry 31, 12477–12485.

63 Holloway DE, Hares MC, Shapiro R, Subramanian V & Acharya KR (2001) High-level expression of three members of the murine angiogenin family in Escherichia coli and purification of the recombinant proteins. Protein Expr Purif 22, 307–317.

64 Pace CN, Vajdos F, Fee L, Grimsley G & Gray T (1995) How to measure and predict the molar absorption coefficient of a protein. Protein Sci 4, 2411–2423.

65 Shapiro R, Riordan JF & Vallee BL (1986) Characteristic ribonucleolytic activity of human angiogenin. Biochemistry 25, 3527–3532.

66 Shapiro R, Weremowicz S, Riordan JF & Vallee BL (1987) Ribonucleolytic activity of angiogenin: essential histidine, lysine, and arginine residues. Proc Natl Acad Sci USA 84, 8783–8787.

67 Otwinowski Z & Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276, 307–326.

68 Minor W, Tomchick D & Otwinowski Z (2000) Strategies for macromolecular synchrotron crystallography. Structure 8, R105–R110.

69 Navaza J (1994) AMoRe: an automated package for molecular replacement. Acta Crystallogr D 50, 157–163.

70 Emsley P & Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60, 2126–2132.

71 Murshudov GN, Vagin AA & Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53, 240–255.

72 Brünger AT (1992) Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. Nature 355, 472–475.

73 Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WB III, Snoeyink J, Richardson JS, et al. (2007) MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res 35, W375–W383.

74 Thompson JD, Gibson TJ & Higgins DG (2002) Multiple sequence alignment using ClustalW and ClustalX. Curr Protoc Bioinformatics Chapter 2, 2.1.1-2.3.22. doi: 10.1002/0471250953.bi2023s00.

75 Bond CS & Schuttelkopf AW (2009) ALINE: a WYSIWYG protein-sequence alignment editor for
publication-quality alignments. *Acta Crystallogr D Biol Crystallogr* **65**, 510–512.

76 Ladner JE, Wladkowski BD, Svensson LA, Sjölin L & Gilliland GL (1997) X-ray structure of a ribonuclease A-uridine vanadate complex at 1.3 Å resolution. *Acta Crystallogr D Biol Crystallogr* **53**, 290–301.

77 McDonald IK & Thornton JM (1994) Satisfying hydrogen bonding potential in proteins. *J Mol Biol* **238**, 777–793.

78 Bailey S (1994) The CCP4 suite: programs for protein crystallography. *Acta Crystallogr D Biol Crystallogr* **50**, 760–763.